Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS171 in Healthy Participants and Participants With Autoimmune Disease
NCT05418101Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Interleukins
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of VIS171 in autoimmune disease (8 cohorts), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Treatment-emergent adverse events at Day 71. Started Apr 2022; status: completed.
02
Drugs
VIS171
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT05418101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05418101.